CNPR Clinical Trials 3 — Questions and Answers
Question 1: What is a 'surrogate endpoint' in a clinical trial?
- A backup primary endpoint used if the main endpoint is unachievable
- A biomarker or lab measure used as a substitute for a clinically meaningful outcome (Correct answer)
- An endpoint assessed by a surrogate (substitute) investigator
- A secondary endpoint elevated to primary status mid-trial
Correct answer: A biomarker or lab measure used as a substitute for a clinically meaningful outcome
A surrogate endpoint is a biomarker (e.g., blood pressure, viral load) believed to predict a clinical outcome, used to expedite drug evaluation.
Question 2: What is the key difference between efficacy and effectiveness in drug evaluation?
- Efficacy measures cost; effectiveness measures clinical outcomes
- Efficacy is measured under ideal controlled conditions; effectiveness is measured in real-world settings (Correct answer)
- Efficacy applies to Phase I trials; effectiveness applies to Phase IV
- Efficacy is assessed by the FDA; effectiveness is assessed by the sponsor
Correct answer: Efficacy is measured under ideal controlled conditions; effectiveness is measured in real-world settings
Efficacy refers to how well a drug performs under controlled trial conditions, while effectiveness reflects performance in real-world clinical practice.
Question 3: Which FDA designation is granted to drugs that treat serious conditions and fill an unmet medical need, allowing faster approval?
- Orphan Drug Designation
- Accelerated Approval
- Breakthrough Therapy Designation (Correct answer)
- Priority Review
Correct answer: Breakthrough Therapy Designation
Breakthrough Therapy Designation allows intensive FDA guidance and expedited development for drugs that show substantial improvement over existing therapies for serious conditions.
Question 4: What is the purpose of stratified randomization in a clinical trial?
- To reduce the total number of participants needed
- To ensure balance of key prognostic factors across treatment groups (Correct answer)
- To allow participants to choose their preferred treatment arm
- To eliminate the need for a placebo group
Correct answer: To ensure balance of key prognostic factors across treatment groups
Stratified randomization ensures important prognostic variables (e.g., age, disease severity) are balanced across treatment groups, reducing confounding.
Question 5: What does 'crossover design' mean in a clinical trial?
- The trial is conducted across multiple countries simultaneously
- Participants receive both the active treatment and control in sequential periods (Correct answer)
- The sponsor and FDA cross-review each other's findings
- Two investigational drugs are compared head-to-head
Correct answer: Participants receive both the active treatment and control in sequential periods
In a crossover design, each participant serves as their own control by receiving both treatments in different time periods, increasing statistical efficiency.
Question 6: Which analysis approach in clinical trials includes data from all randomized participants regardless of protocol adherence?
- Per-protocol analysis
- Intention-to-treat analysis (Correct answer)
- Sensitivity analysis
- Subgroup analysis
Correct answer: Intention-to-treat analysis
Intention-to-treat (ITT) analysis includes all randomized participants in their originally assigned group, preserving the benefits of randomization and reflecting real-world conditions.
Question 7: What is a Phase IV clinical trial also known as?
- Dose-finding study
- Pivotal trial
- Post-marketing surveillance study (Correct answer)
- First-in-human study
Correct answer: Post-marketing surveillance study
Phase IV trials, also called post-marketing surveillance studies, monitor a drug's long-term safety and effectiveness after FDA approval in the general population.
CNPR Clinical Trials 3
What is a 'surrogate endpoint' in a clinical trial?